TP53 and ovarian carcinoma: According to Peck et al., inhibition of SIRT1 increases p53 acetylation and triggers apoptosis, whereas elevated SIRT1 activity correlates with earlier relapse and reduced sensitivity to ROS-inducing agents in patients with ovarian cancer [86].